Background/Aims: Sphingosine-1-phosphate (S1P) is a bioactive lysosphingolipid that is found in high concentration in plasma. The majority of plasma S1P is transported bound to HDL and albumin. Although the major sources of circulating S1P have been identified, it remains obscure what is the contribution of different organs/tissues to S1P homeostasis in plasma. Answering this question was the major aim of the present study. Methods: The experiment was performed on male Wistar rats from whom blood samples were taken from either: 1) femoral vein, right ventricle of the heart, and abdominal aorta (n=15) or 2) hepatic vein, portal vein, and abdominal aorta (n=11). Plasma was fractionated by sequential flotation ultracentrifugation and sphingolipids were quantified by a HPLC method. Results: Compared to the mixed venous blood sampled from the right ventricle, total plasma and lipoproteindepleted plasma (LPDP) concentration of S1P in the arterial blood was lower. On the other hand, the level of S1P increased across the leg both in plasma and LPDP. The concentration of S1P, sphingosine, and sphinganine in the plasma, HDL, and LPDP isolated from the blood taken from the hepatic vein was markedly higher compared to both arterial and portal blood. Conclusions: We conclude that, in contrast to HDL-bound S1P, albumin-associated S1P is very labile in the circulation. It is degraded in the pulmonary, and to a lesser extent, gastrointestinal circulation, and released across the liver and skeletal muscle. We also conclude that liver is an important source of HDL-bound S1P and circulating free sphingoid bases.
Introduction
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that has been shown to act by binding to a family of five specific G protein-coupled receptors (S1PR [1] [2] [3] [4] [5] ) [1] . S1P is produced in all cells by sphingosine kinase (SphK)-mediated phosphorylation of sphingosine (a catabolite of ceramide), and may be subsequently released to the extracellular milieu with the help of spinster homolog 2 (SPNS2), ATP-binding cassette transporter C1, and major facilitator superfamily transporter 2b [2] [3] [4] . In addition to sphingosine, SphK is also able to phosphorylate sphinganine (an intermediate of ceramide de novo synthesis pathway) to form sphinganine-1-phosphate (SA1P) [5] . SA1P was shown to activate S1PRs with a potency comparable to that of S1P [6] . Sphingoid base-1-phosphates can be converted back to free sphingoid bases by the action of S1P phosphatase and lipid phosphate phosphatase (LPP), or irreversibly degraded by S1P lyase to fatty aldehyde and ethanolamine phosphate [7] .
In addition to solid tissues, S1P is found also in blood. Large amounts of S1P are stored in erythrocytes and platelets which possess highly active SphK [8] . In the plasma S1P is transported bound to high-density lipoprotein HDL (50-60%), albumin (30-40%), and to a much lesser extent to low-(LDL) and very low-density (VLDL) lipoproteins [9] [10] [11] . Apolipoprotein M (ApoM) was found to be the major carrier of S1P in HDL [12] . Interestingly, the type of carrier strongly affects properties of circulating S1P. HDL-bound S1P is characterized by greater biological activity and much longer half-life compared to albumin-associated S1P [13] [14] [15] [16] .
The major sources of circulating S1P include erythrocytes, vascular endothelial cells (ECs), and hepatocytes [17] [18] [19] . However, their relative contribution to the plasma S1P pool is unclear [8] . It should be noted that vascular ECs not only release but also degrade extracellular S1P with the help of LPP1 expressed on the outer surface of their plasma membrane [20] .
Although the major cellular sources of circulating S1P have been identified, it remains obscure what is the contribution of different organs/tissues to S1P homeostasis in plasma. Moreover, the source of circulating free sphingoid bases, which are utilized as substrates for sphingoid base-1-phosphates synthesis in blood cells, have not been identified so far. We have previously found that S1P level in the arterial plasma is lower compared to the venous one, and that skeletal muscle releases sphingosine to the circulation during intense exercise [21] . These findings prompted us to examine arteriovenous differences in plasma sphingolipid concentrations across selected organs of the rat. pentobarbital (45mg/kg of body weight). Rats were randomly divided into two groups and 1.2ml blood samples were taken from either 1) femoral vein, right ventricle of the heart, and abdominal aorta (n=15) or 2) hepatic vein, portal vein, and abdominal aorta (n=11) (Fig. 1 ). This approach was chosen in order to minimize circulatory changes related to hypovolemia (the total volume of blood lost before taking the last sample was only ~10%).
Materials and Methods

Animals and experimental design
In the first group the procedure started with the opening of the abdomen, and then the right femoral vein was exposed from which the first blood sample was taken. Next, the chest was opened and blood samples were quickly taken from the right ventricle of the heart, and then from the abdominal aorta. In the second group after opening of the abdomen a tracheal cannula was inserted and secured following tracheotomy. The tube was connected to a rodent respirator that supplied artificial ventilation for the rat after subsequent opening of the chest and incision of the diaphragm to expose hepatic veins. Next, blood samples were taken (in this specific order) from the left hepatic vein, hepatic portal vein, and abdominal aorta. The vessels chosen for blood sampling were selected on the basis of previous studies indicating that lungs, liver and skeletal muscle may play an important role in S1P homeostasis in plasma [19, 20, 22, 23] .
All blood samples were collected by free flow from the catheter into the 1.2ml EDTA tubes which were immediately put on ice to prevent S1P release from erythrocytes [24] . Blood was then centrifuged at 1950×g for 10 min at 4°C. The supernatant was transferred to a fresh tube and recentrifuged at 5000×g for 10 min at 4°C to obtain platelet-free plasma.
Isolation of lipoproteins
Lipoproteins were isolated from the platelet-free plasma by sequential flotation ultracentrifugation in NaBr solution in a Sorvall RC M120 GX ultracentrifuge using a S120-AT2 rotor (Thermo Scientific, Waltham, MA) as described by Havel et al. [25] with some modifications. Briefly, 600μL of plasma was centrifuged at 120, 000 rpm for 85 min at 8°C at a density of 1.006 g/mL to remove VLDL, for 155 min at a density of 1.063 g/mL to obtain LDL, and for 260 min at a density of 1.21 g/mL to obtain HDL. After the last centrifugation step 300μL of lipoprotein-depleted plasma (LPDP) were recovered from the bottom of the tube. To avoid oxidation of lipoproteins, EDTA was present in all preparation steps. Densities of NaBr solutions used for density adjustments were checked with a digital densitometer (Mettler Toledo, Greifensee, Switzerland).
Determination of protein and cholesterol concentrations
Cholesterol concentration in HDL and LDL isolates was measured using diagnostic reagent for determination of total cholesterol concentration (BioMaxima, Lublin, Poland). Protein concentration in LPDP was measured with the BCA protein assay kit (Sigma, St. Luis, MO). Bovine serum albumin (fatty acid free, Sigma) was used as a standard.
Sphingolipid analysis
All samples were stored at -80°C until analysis. The content of S1P, SA1P, sphingosine, sphinganine, and ceramide was determined as described previously in detail [26] . Briefly, lipids were extracted from samples in the presence of internal standards (C 17 -sphingosine and C 17 -S1P, Avanti Polar Lipids, Alabaster, AL). An aliquot of the lipid extract was transferred to a fresh tube with pre-added N-palmitoyl-D-erythrosphingosine (C17 base) (a kind gift of Dr Z. Szulc, Medical University of South Carolina) as an internal standard, and then subjected to alkaline hydrolysis to deacylate ceramide to sphingosine. The amount of S1P and SA1P was determined indirectly after dephosphorylation to sphingosine and sphinganine, respectively, with the use of alkaline phosphatase (bovine intestinal mucosa, Sigma). Free sphingosine and sphinganine, dephosphorylated sphingoid bases, and sphingosine released from ceramide were then converted to their o-phthalaldehyde derivatives and analyzed using a HPLC system (ProStar, Varian Inc., Palo Alto, CA) equipped with a fluorescence detector and C18 reversed-phase column (Varian Inc. OmniSpher 5, 4.6´150mm). The isocratic eluent composition of acetonitrile (Merck, Darmstadt, Germany): water (9:1, v/v) and a flow rate of 1 mL/min were used. Column temperature was maintained at 30°C.
Calculations and statistical analysis
Sphingolipid concentration in mixed portal and arterial plasma was calculated using weighted averages of sphingolipid levels determined in samples taken from these blood vessels, assuming that 80% of total liver blood flow was supplied by the portal vein [27, 28] . All data are presented as means ± SD. Statistical comparisons were made by using either repeated measures ANOVA followed by Newman-Keuls test, or Student's t-test for paired samples. P<0.05 was considered statistically significant.
Results
Total plasma sphingolipids
There were no statistically significant differences in the concentration of ceramide either in plasma or in any of its fractions (data not shown). Compared to the mixed venous blood sampled from the right ventricle, total plasma concentration of sphingosine, sphinganine, S1P, and SA1P in the arterial blood was lower (by 28, 37, 26 and 20%, respectively). On the other hand, the plasma level of free sphingoid bases in blood taken from the femoral vein was not different to that sampled from the abdominal aorta (Fig. 2) . However, the concentration of sphingoid base-1-phosphates increased across the leg. There were no statistically significant differences in the concentration of any of the measured sphingolipids between the arterial and portal plasma. The level of free sphingoid bases and sphingoid base-1-phosphates in the plasma isolated from the blood taken from the hepatic vein was markedly higher compared to both arterial and portal blood (Fig. 2) . Statistically significant increase for all of the above sphingolipids was also observed when their plasma concentrations in the blood sampled from the hepatic vein were compared to the estimated values in the mixed portal and arterial blood (Fig. 3 ). All significant differences described above were confirmed by statistically significant difference from zero of arteriovenous differences in plasma sphingolipid concentration (Table 1) .
HDL-bound sphingolipids
Compared to the mixed venous blood from the right ventricle, concentration of sphingosine and sphinganine (but not S1P or SA1P) in the arterial HDL was lower (by 27 and 30%, respectively). On the other hand, the concentration of either of the examined sphingolipids in HDL did not change across the leg (Fig. 2 ). There were also no statistically significant differences in the concentration of the measured sphingolipids in HDL between the abdominal aorta and portal vein. In general, the concentration of free sphingoid bases and sphingoid base-1-phosphates in HDL isolated from blood taken from the hepatic vein was higher compared to both arterial and portal blood. However, for S1P the difference between the abdominal aorta and hepatic vein did not reach statistical significance (Fig.  2) . When HDL concentrations of the above-mentioned sphingolipids in the hepatic vein were compared to the estimated values in the mixed portal and arterial blood a significant increase was observed in all cases (Fig. 3) . Analysis of arteriovenous differences in HDLbound sphingolipid concentration confirmed all significant differences between blood vessels described above. In addition, a statistically significant uptake of HDL-associated ceramide was found across the digestive tract (Table 1) .
LDL-bound sphingolipids
When LDL concentrations of sphingolipids in the mixed venous blood were compared to the arterial ones a significant difference was observed only for sphinganine (a 34% decrease). On the other hand, the concentration of either of the measured sphingolipids in LDL did not change across the leg. There were also no statistically significant differences between arterial and portal blood (Fig. 2) . The concentration of sphinganine and SA1P in LDL isolated from the blood taken from the hepatic vein was higher compared to the portal blood. For sphinganine a similar difference was observed also between the hepatic vein and abdominal aorta (Fig. 2) . When LDL concentrations of sphingolipids in the hepatic vein were compared to the estimated values in the mixed portal and arterial blood a significant increase was Cellular Physiology and Biochemistry
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found only for sphinganine and S1P (Fig. 3 ). All significant differences described above were confirmed by analysis of arteriovenous differences in LDL-bound sphingolipid concentration. In addition, a statistically significant uptake of LDL-associated sphingosine, S1P, and SA1P across lungs, as well as sphinganine across the digestive tract was found. Moreover, a release of sphinganine, S1P, and SA1P was observed across the leg (Table 1) .
Sphingolipids in LPDP
Compared to the mixed venous blood, concentration of sphingosine, sphinganine, S1P, and SA1P in the arterial LPDP was markedly lower (by 54, 40, 44, and 31%, respectively). The concentration of free sphingoid bases in LPDP did not change across the leg, whereas, a significant increase was observed for S1P and SA1P (Fig. 2) . Similarly to lipoprotein fractions, there were no statistically significant differences in the concentration of the measured sphingolipids between arterial and portal LPDP. The level of free sphingoid bases and sphingoid base-1-phosphates in the LPDP isolated from samples taken from the hepatic vein was 2-to 3-fold higher compared to both arterial and portal blood (Fig. 2) . Statistically significant increase for all of the above sphingolipids was also observed when their LPDP concentrations in the hepatic vein were compared to the estimated values in the mixed portal and arterial blood (Fig. 3) . Analysis of arteriovenous differences in sphingolipid concentration in LPDP confirmed all significant differences between blood vessels described above. In addition, a statistically significant release of sphingosine across the leg, as well as uptake of sphingosine, sphinganine, and S1P across the digestive tract was observed (Table  1) .
Discussion
To the best of our knowledge this is the first report describing arteriovenous differences in sphingolipid concentration across various organs. We showed that in the pulmonary circulation large amounts of sphingoid base-1-phosphates were removed from the plasma. This observation is not surprising since many biologically active compounds (e.g. serotonin, norepinephrine, and bradykinin) were previously found to be degraded or uptaken by the ECs of the pulmonary circulation [29] . Zhao et al. [20] reported that ECs from macro-and microvessels of human pulmonary circulation rapidly degrade extracellular S1P and SA1P via the action of LPP1. It is, therefore, most likely that the decrease in sphingoid base-1-phosphates concentration across lungs observed in our study resulted from their degradation by the vascular ECs. The fact that this effect resulted almost exclusively from the decrease in S1P and SA1P content in LPDP, whereas the concentration of HDL-associated sphingoid base-1-phosphates remained stable, is also consistent with this hypothesis. It was found that ApoM-bound S1P has a much longer half-life in vivo compared to albumin-bound S1P [13, 16] . In addition, the rate of degradation of HDL-bound S1P by the vascular ECs was reported to be markedly lower compared to the albumin-associated S1P [30] . A similar, albeit much weaker, decrease in S1P concentration in LPDP was also observed across the digestive tract. Fig. 3 . Percent differences in concentrations of sphingolipids between the mixed arterial and portal blood, and blood sampled from the hepatic vein. The dotted line represents the mean concetration in the mixed arterial and portal blood which was arbitrally set as 100%. Sphingolipid concentrations in the mixed portal and arterial blood were calculated assuming that 80% of total liver blood flow was supplied by the portal vein. The results are means ± SD (n=11). * -p<0.05 vs the mixed arterial and portal blood. HDL -highdensity lipoprotein, LDL -low-density lipoprotein, LPDP -lipoprotein-depleted plasma.
The fact that dephosphorylation of sphingoid base-1-phosphates in the pulmonary and gastrointestinal circulation was associated with a marked decrease, rather than increase, in the content of free sphingoid bases may seem puzzling. However, in vitro studies showed that free sphingoid bases released by the action of LPP1 found on the surface of the vascular ECs are not released to the medium but rapidly absorbed and used to generate intracellular S1P and SA1P [20] .
In contrast to the pulmonary circulation, S1P and SA1P were not removed but released across the leg. This observation is in line with the results of our previous human study [21] . Interestingly, the increase in sphingoid base-1-phosphates concentration was observed in LPDP and LDL, but not in HDL. Vascular ECs were shown to not only degrade but also export S1P. Spontaneous release of S1P was confirmed for vascular ECs from human umbilical vein, human pulmonary artery, and murine aorta, as well as for mouse embryonic ECs [2, 16, [31] [32] [33] . Our results strongly suggest that the relative rate of S1P release and degradation by vascular ECs varies among different vascular beds. Degradation seems to prevail in the pulmonary and gastrointestinal circulation, whereas release dominates in the hepatic and skeletal muscle circulation. The results of our previous human study support the notion that vascular ECs simultaneously degrade and export plasma S1P. We showed that at rest S1P was released across the leg, whereas during the exercise it was rapidly degraded in the same vascular bed [21] . It was also found that endothelial expression of SPNS2 (the protein transporter responsible for S1P export from vascular ECs) differs among vascular beds of various organs in mice [2] . In addition, SPNS2 expression was shown to be higher in the venous ECs compared to the arterial ones [31] which could also contribute to the observed increase in S1P concentration in the femoral vein.
In our study the greatest arteriovenous differences in plasma sphingolipid concentrations were found for the liver. In the hepatic circulation large amounts of both albumin-and HDLbound sphingoid base-1-phosphates were released. This is in contrast to other vascular beds where the concentration of S1P and SA1P in HDL remained stable. It was previously found that plasma S1P concentration is reduced in chronic hepatitis C patients, rats with tetrachloride-induced liver fibrosis, and after partial hepatectomy in mice [19, 34] . Our results further support the notion that liver constitutes an important source of circulating S1P. It was shown that murine primary hepatocytes and HepG2 cells are able to release S1P [16, 19, 35] . Moreover, liver is the source of plasma ApoM, the major S1P-binding protein in HDL [12, 36] . This is likely the reason why HDL-bound S1P was released across the liver but not other vascular beds examined in our study. ApoM is highly expressed also in renal tubular epithelial cells which suggests that kidneys may play some role in homeostasis of circulating S1P [36] .
Salous et al. [22] reported that in mice as much as 86% of intravenously infused 17-carbon analog of S1P is dephosphorylated and accumulates in the liver which strongly suggests intensive degradation of circulating S1P in the hepatic circulation. This is in contrast to our study where marked release of S1P was found across the liver. However, Salous et al. estimated only sphingoid base-1-phosphate degradation (they used an S1P analog that is normally not released by cells), whereas we determined the net effect of S1P degradation and release in the hepatic circulation. Therefore, our results indicate that in the rat liver the rate of sphingoid base-1-phosphates release markedly exceeds their degradation.
In addition, we found that large amounts of sphingosine and sphinganine are released across the hepatic circulation. To the best of our knowledge this is the first identified source of circulating free sphingoid bases. This finding is of importance since blood cells incorporate sphingosine from plasma and use it as a substrate for S1P synthesis [24] .
To date, several physiological roles have been attributed to the circulating S1P. Specifically, stimulation of lymphocyte egress from lymphoid organs to blood, maintenance of endothelial barrier integrity, regulation of vascular tone, heart function, and bone homeostasis [17, [37] [38] [39] . Recent data strongly suggests that among different plasma S1P pools, HDL-bound S1P is the one that plays the most prominent role in regulation of both physiological and pathophysiological processes. For instance, ApoM-deficient mice are Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry characterized by markedly increased pulmonary vascular permeability, and reconstitution of plasma ApoM/S1P rapidly reverses the vascular leakage [40] . Blaho et al [41] . demonstrated that HDL-bound S1P specifically restrains bone marrow lymphopoiesis, and reduces neuroinflammation in experimental autoimmune encephalomyelitis. HDL-associated S1P was also shown to exert anti-inflammatory and antiatherosclerotic effects in the vascular endothelium [42] . In addition, HDL-bound S1P was recently found to promote regeneration and suppress fibrosis in the liver, as well as to attenuate hypertension and ischemic injury [13, 43] .
Conclusion
In summary, we found that under physiological conditions the level of free sphingoid bases and sphingoid base-1-phosphates in plasma is not stable and is subjected to acute changes during transfer of blood through the circulatory system. Moreover, the magnitude and direction of these changes varies considerably between different vascular beds and plasma sphingolipid pools. We conclude that, in contrast to HDL-bound S1P, albuminassociated S1P is very labile in the circulation. It is degraded in the pulmonary, and to a lesser extent, gastrointestinal circulation, and released across the liver and skeletal muscle. We also conclude that liver is an important source of HDL-bound S1P and circulating free sphingoid bases.
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